[go: up one dir, main page]

WO2007123848A3 - Therapeutic compositions containing modified class i slrp proteins - Google Patents

Therapeutic compositions containing modified class i slrp proteins Download PDF

Info

Publication number
WO2007123848A3
WO2007123848A3 PCT/US2007/009091 US2007009091W WO2007123848A3 WO 2007123848 A3 WO2007123848 A3 WO 2007123848A3 US 2007009091 W US2007009091 W US 2007009091W WO 2007123848 A3 WO2007123848 A3 WO 2007123848A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic compositions
slrp
proteins
compositions containing
containing modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/009091
Other languages
French (fr)
Other versions
WO2007123848A2 (en
Inventor
Justin R Fallon
Beth Mckechnie
Alison Rosalind Amenta
Mary Lynn Mercado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brown University
Original Assignee
Brown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brown University filed Critical Brown University
Publication of WO2007123848A2 publication Critical patent/WO2007123848A2/en
Anticipated expiration legal-status Critical
Publication of WO2007123848A3 publication Critical patent/WO2007123848A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Therapeutic compositions and methods of treating, and preventing the onset of neuromuscular disorders, conditions or diseases in mammals, especially in humans, including for example the muscular dystrophies and especially DMD and BMD, are provided. The therapeutic compositions include effective amount of one or more non- glycanated Class I SLRP proteins alone or in admixture with a pharmaceutically acceptable vehicle. The therapeutic pharmaceutical compositions of the invention may be administered alone or in combination with each other and/or in combination with other therapeutic compositions.
PCT/US2007/009091 2006-04-19 2007-04-13 Therapeutic compositions containing modified class i slrp proteins Ceased WO2007123848A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79329206P 2006-04-19 2006-04-19
US60/793,292 2006-04-19

Publications (2)

Publication Number Publication Date
WO2007123848A2 WO2007123848A2 (en) 2007-11-01
WO2007123848A3 true WO2007123848A3 (en) 2008-11-27

Family

ID=38625522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/009091 Ceased WO2007123848A2 (en) 2006-04-19 2007-04-13 Therapeutic compositions containing modified class i slrp proteins

Country Status (1)

Country Link
WO (1) WO2007123848A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612038B2 (en) 1999-11-18 2009-11-03 Brown University Biglycan and related therapeutics and methods of use
US6864236B1 (en) 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use
EP1423133B1 (en) 2001-08-15 2009-01-14 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
PT3103800T (en) 2003-04-11 2018-07-27 Ptc Therapeutics Inc 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
FR2943249B1 (en) * 2009-03-18 2011-08-12 Genethon USE OF DECORINE TO INCREASE MUSCLE MASS
CA2799735C (en) 2010-05-17 2019-06-25 Brown University Biglycan mutants and related therapeutics and methods of use
EP3026432A3 (en) * 2010-12-27 2016-07-27 Brown University Method for predicting patient's response to biglycan treatment
WO2014059013A1 (en) 2012-10-10 2014-04-17 Tivorsan Pharmaceuticals, Inc. Biglycan variant polypeptides and methods of use
KR102497273B1 (en) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
CA3003132A1 (en) 2015-10-30 2017-05-04 Ptc Therapeutics, Inc. Methods for treating epilepsy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864236B1 (en) * 1999-11-18 2005-03-08 Brown University Research Foundation Biglycan and related therapeutics and methods of use

Also Published As

Publication number Publication date
WO2007123848A2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2007123848A3 (en) Therapeutic compositions containing modified class i slrp proteins
WO2004009558A3 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
WO2007101224A3 (en) Inhibitors of the unfolded protein response and methods for their use
WO2008021368A3 (en) Compositions and methods for neuroprotection
UA94909C2 (en) Pharmaceutical composition of a neuroactive steroid and use thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2005097125A3 (en) Methods and compositions for the treatment, prevention or management of diysfunctional sleep and dysfunctional sleep associated with disease
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
HK1199726A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2005020972A3 (en) Combination therapy for the treatment of ocular neovascular disorders
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
AU2003210300A1 (en) The use of tnf-alpha antagonist as drugs for the treatment of patients with sepsis and without suffering from total organ failure
WO2006037031A3 (en) Formulations and methods for treatment of inflammatory diseases
WO2005051297A3 (en) Combination drug therapy to treat obesity
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2010045417A3 (en) Combination therapies for the treatment of obesity
WO2007092469A3 (en) Combination of organic compounds
WO2003082196A3 (en) Combination therapy using trefoil peptides
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2006036770A3 (en) Combination therapy for the treatment of obesity
WO2005066337A3 (en) Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07775327

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07775327

Country of ref document: EP

Kind code of ref document: A2